Novavax Announces Launch of Global Vaccine Education Programs
PR94927
GAITHERSBURG, Md., Mar. 11, 2022 /PRNewswire=KYODO JBN/--
- 'We Do Vaccines' and 'Know Our Vax' are new educational efforts that provide
information regarding vaccines
- Programs explain Novavax' commitment to vaccine development and innovation
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing
and commercializing next-generation vaccines for serious infectious diseases,
today announced the launch of its global unbranded 'We Do Vaccines' (
) and 'Know Our Vax' (
) programs, educational efforts aimed to help protect the health of people
everywhere in the fight against COVID-19 and other deadly infectious diseases,
such as influenza.
Photo -
https://mma.prnewswire.com/media/1763609/Novavax_We_Do_Vaccines_Know_Our_Vax_programs.jpg
Logo - https://mma.prnewswire.com/media/1506866/Novavax_High_Res_Logo.jpg
The 'We Do Vaccines' program helps provide educational information about the
common types of vaccines and how they work, how vaccines are made and tested,
and how Novavax' approach to technology makes its vaccines different. The 'Know
Our Vax' program provides educational information about Novavax, its global
approach, and tried and true technology.
"Novavax' vaccines are built on a well-understood protein-based platform used
for other vaccines for decades, and we are committed to fighting the current
pandemic and aiding in overall global public health," said John Trizzino, Chief
Commercial Officer and Chief Business Officer, Novavax. "We're proud to do our
part to ensure that all stakeholders have awareness about their vaccine options
through the launch of educational programs such as these."
The programs intend to inspire people to learn more about how vaccines have
helped millions of lives and encourage those who have not yet been vaccinated
to consider a differentiated option. For additional information, the consumer
website is available at www.wedovaccines.com and the healthcare provider
website is available at www.knowourvax.com.
About Novavax
Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved
health globally through the discovery, development and commercialization of
innovative vaccines to prevent serious infectious diseases. The company's
proprietary recombinant technology platform harnesses the power and speed of
genetic engineering to efficiently produce highly immunogenic nanoparticles
designed to address urgent global health needs. NVX-CoV2373, the company's
COVID-19 vaccine, has received conditional authorization from multiple
regulatory authorities globally, including the European Commission and the
World Health Organization. The vaccine is also under review by multiple
regulatory agencies worldwide. In addition to its COVID-19 vaccine, Novavax is
also currently evaluating a COVID-seasonal influenza combination vaccine in a
Phase 1/2 clinical trial, which combines NVX-CoV2373 and NanoFlu, its
quadrivalent influenza investigational vaccine candidate. These vaccine
candidates incorporate Novavax' proprietary saponin-based Matrix-M(TM) adjuvant
to enhance the immune response and stimulate high levels of neutralizing
antibodies.
For more information, visit: www.novavax.com and connect with us on Twitter (
https://twitter.com/Novavax ) , LinkedIn (
https://www.linkedin.com/company/novavax/ ), Instagram (
https://www.instagram.com/novavax/ ) and Facebook (
https://www.facebook.com/Novavax/ ).
Forward-Looking Statements
Statements herein relating to the future of Novavax, its operating plans and
prospects, its partnerships, the timing of clinical trial results, the ongoing
development of NVX-CoV2373, including a COVID-seasonal influenza combination
vaccine candidate with NanoFlu, its quadrivalent influenza investigational
vaccine candidate, the scope, timing and outcome of future regulatory filings
and actions, the potential impact of Novavax and NVX-CoV2373 in addressing
global vaccine access and education, controlling the pandemic, and protecting
populations, and the efficacy, safety, and intended utilization of NVX-CoV2373
are forward-looking statements. Novavax cautions that these forward-looking
statements are subject to numerous risks and uncertainties that could cause
actual results to differ materially from those expressed or implied by such
statements. These risks and uncertainties include, without limitation,
challenges satisfying, alone or together with partners, various safety,
efficacy, and product characterization requirements, including those related to
process qualification and assay validation, necessary to satisfy applicable
regulatory authorities; unanticipated challenges or delays in conducting
clinical trials; difficulty obtaining scarce raw materials and supplies;
resource constraints, including human capital and manufacturing capacity, on
the ability of Novavax to pursue planned regulatory pathways; challenges
meeting contractual requirements under agreements with multiple commercial,
governmental, and other entities; and those other risk factors identified in
the "Risk Factors" and "Management's Discussion and Analysis of Financial
Condition and Results of Operations" sections of Novavax' Annual Report on Form
10-K for the year ended December 31, 2021, as filed with the Securities and
Exchange Commission (SEC). We caution investors not to place considerable
reliance on forward-looking statements contained in this press release. You are
encouraged to read our filings with the SEC, available at www.sec.gov and
www.novavax.com, for a discussion of these and other risks and uncertainties.
The forward-looking statements in this press release speak only as of the date
of this document, and we undertake no obligation to update or revise any of the
statements. Our business is subject to substantial risks and uncertainties,
including those referenced above. Investors, potential investors, and others
should give careful consideration to these risks and uncertainties.
Contacts:
Investors:
Novavax, Inc.
Erika Schultz
+1-240-268-2022
ir@novavax.com
Solebury Trout
Alexandra Roy
+1-617-221-9197
aroy@soleburytrout.com;
Media:
Ali Chartan
+1-240-720-7804
Laura Keenan Lindsey
+1-202-709-7521
media@novavax.com
SOURCE: Novavax, Inc.
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。